Published in Am J Pathol on February 01, 2005
A mouse model for Chikungunya: young age and inefficient type-I interferon signaling are risk factors for severe disease. PLoS Pathog (2008) 3.40
Cryptococcal cell morphology affects host cell interactions and pathogenicity. PLoS Pathog (2010) 2.28
Evidence of a role for monocytes in dissemination and brain invasion by Cryptococcus neoformans. Infect Immun (2008) 2.15
The capsule of the fungal pathogen Cryptococcus neoformans. Adv Appl Microbiol (2009) 1.97
Real-time imaging of trapping and urease-dependent transmigration of Cryptococcus neoformans in mouse brain. J Clin Invest (2010) 1.67
The cryptococcal enzyme inositol phosphosphingolipid-phospholipase C confers resistance to the antifungal effects of macrophages and promotes fungal dissemination to the central nervous system. Infect Immun (2006) 1.60
The Cryptococcus neoformans capsule: a sword and a shield. Clin Microbiol Rev (2012) 1.45
How sweet it is! Cell wall biogenesis and polysaccharide capsule formation in Cryptococcus neoformans. Annu Rev Microbiol (2009) 1.43
Specific antibody can prevent fungal biofilm formation and this effect correlates with protective efficacy. Infect Immun (2005) 1.42
The relative susceptibility of mouse strains to pulmonary Cryptococcus neoformans infection is associated with pleiotropic differences in the immune response. Infect Immun (2007) 1.30
Cryptococcus neoformans capsular enlargement and cellular gigantism during Galleria mellonella infection. PLoS One (2011) 1.29
Radial mass density, charge, and epitope distribution in the Cryptococcus neoformans capsule. Eukaryot Cell (2006) 1.21
Immune restoration diseases reflect diverse immunopathological mechanisms. Clin Microbiol Rev (2009) 1.21
Capsule of Cryptococcus neoformans grows by enlargement of polysaccharide molecules. Proc Natl Acad Sci U S A (2009) 1.19
Immortalized human brain endothelial cell line HCMEC/D3 as a model of the blood-brain barrier facilitates in vitro studies of central nervous system infection by Cryptococcus neoformans. Eukaryot Cell (2009) 1.17
Cryptococcal neuroradiological lesions correlate with severity during cryptococcal meningoencephalitis in HIV-positive patients in the HAART era. PLoS One (2008) 1.14
Phospholipids trigger Cryptococcus neoformans capsular enlargement during interactions with amoebae and macrophages. PLoS Pathog (2011) 1.11
Cryptococci at the brain gate: break and enter or use a Trojan horse? J Clin Invest (2010) 1.09
Phenotypic switching in a Cryptococcus neoformans variety gattii strain is associated with changes in virulence and promotes dissemination to the central nervous system. Infect Immun (2006) 1.05
Evidence for branching in cryptococcal capsular polysaccharides and consequences on its biological activity. Mol Microbiol (2011) 1.01
Surface-associated plasminogen binding of Cryptococcus neoformans promotes extracellular matrix invasion. PLoS One (2009) 0.98
Multiple Disguises for the Same Party: The Concepts of Morphogenesis and Phenotypic Variations in Cryptococcus neoformans. Front Microbiol (2011) 0.98
Molecular mechanisms of cryptococcal meningitis. Virulence (2012) 0.97
Blood-brain barrier invasion by Cryptococcus neoformans is enhanced by functional interactions with plasmin. Microbiology (2011) 0.97
Emerging themes in cryptococcal capsule synthesis. Curr Opin Struct Biol (2011) 0.96
Lipid raft/caveolae signaling is required for Cryptococcus neoformans invasion into human brain microvascular endothelial cells. J Biomed Sci (2012) 0.95
Ten challenges on Cryptococcus and cryptococcosis. Mycopathologia (2011) 0.95
Cryptococcus neoformans responds to mannitol by increasing capsule size in vitro and in vivo. Cell Microbiol (2010) 0.95
Cryptococcus neoformans: historical curiosity to modern pathogen. Yeast (2014) 0.94
Congenic strains of the filamentous form of Cryptococcus neoformans for studies of fungal morphogenesis and virulence. Infect Immun (2013) 0.94
The elastic properties of the Cryptococcus neoformans capsule. Biophys J (2009) 0.94
Eosinophils contribute to IL-4 production and shape the T-helper cytokine profile and inflammatory response in pulmonary cryptococcosis. Am J Pathol (2011) 0.93
Capsular Material of Cryptococcus neoformans: Virulence and Much More. Mycopathologia (2012) 0.90
Cryptococcus neoformans phospholipase B1 activates host cell Rac1 for traversal across the blood-brain barrier. Cell Microbiol (2012) 0.90
Unusual galactofuranose modification of a capsule polysaccharide in the pathogenic yeast Cryptococcus neoformans. J Biol Chem (2013) 0.89
Brain inositol is a novel stimulator for promoting Cryptococcus penetration of the blood-brain barrier. PLoS Pathog (2013) 0.88
Phenotypic heterogeneity in expression of epitopes in the Cryptococcus neoformans capsule. Mol Microbiol (2009) 0.88
Chronological aging is associated with biophysical and chemical changes in the capsule of Cryptococcus neoformans. Infect Immun (2011) 0.87
Invasion of the central nervous system by Cryptococcus neoformans requires a secreted fungal metalloprotease. MBio (2014) 0.86
Cryptococcus neoformans promotes its transmigration into the central nervous system by inducing molecular and cellular changes in brain endothelial cells. Infect Immun (2013) 0.85
Fungal-induced cell cycle impairment, chromosome instability and apoptosis via differential activation of NF-κB. PLoS Pathog (2012) 0.85
Mannoprotein MP84 mediates the adhesion of Cryptococcus neoformans to epithelial lung cells. Front Cell Infect Microbiol (2014) 0.84
Cryptococcosis Serotypes Impact Outcome and Provide Evidence of Cryptococcus neoformans Speciation. MBio (2015) 0.84
Identification of genes from the fungal pathogen Cryptococcus neoformans related to transmigration into the central nervous system. PLoS One (2012) 0.83
Cryptococcus neoformans induces antimicrobial responses and behaves as a facultative intracellular pathogen in the non mammalian model Galleria mellonella. Virulence (2015) 0.82
Cryptococcus neoformans host adaptation: toward biological evidence of dormancy. MBio (2015) 0.82
Antigenic and phenotypic variations in fungi. Cell Microbiol (2009) 0.82
Intravascular clearance of disseminating Cryptococcus neoformans in the brain can be improved by enhancing neutrophil recruitment in mice. Eur J Immunol (2016) 0.81
Capsule independent uptake of the fungal pathogen Cryptococcus neoformans into brain microvascular endothelial cells. PLoS One (2012) 0.81
Experimental models of cryptococcosis. Int J Microbiol (2011) 0.81
Acute/subacute cerebral infarction (ASCI) in HIV-negative adults with cryptococcal meningoencephalitis (CM): a MRI-based follow-up study and a clinical comparison to HIV-negative CM adults without ASCI. BMC Neurol (2011) 0.81
Synthesis of cell envelope glycoproteins of Cryptococcus laurentii. Carbohydr Res (2007) 0.80
Cryptococcus and Phagocytes: Complex Interactions that Influence Disease Outcome. Front Microbiol (2016) 0.79
Immunomodulation with CD40 stimulation and interleukin-2 protects mice from disseminated cryptococcosis. Infect Immun (2006) 0.79
The choroid plexus-a multi-role player during infectious diseases of the CNS. Front Cell Neurosci (2015) 0.78
Cryptococcus inositol utilization modulates the host protective immune response during brain infection. Cell Commun Signal (2014) 0.78
Variability of phenotypic traits in Cryptococcus varieties and species and the resulting implications for pathogenesis. Future Microbiol (2010) 0.78
Trojan Horse Transit Contributes to Blood-Brain Barrier Crossing of a Eukaryotic Pathogen. MBio (2017) 0.78
Effect of amphotericin B on capsule and cell size in Cryptococcus neoformans during murine infection. Antimicrob Agents Chemother (2005) 0.77
Aging as an emergent factor that contributes to phenotypic variation in Cryptococcus neoformans. Fungal Genet Biol (2014) 0.77
Allergen1 regulates polysaccharide structure in Cryptococcus neoformans. Mol Microbiol (2013) 0.77
Cryptococcus neoformans hyperfilamentous strain is hypervirulent in a murine model of cryptococcal meningoencephalitis. PLoS One (2014) 0.76
A Small Protein Associated with Fungal Energy Metabolism Affects the Virulence of Cryptococcus neoformans in Mammals. PLoS Pathog (2016) 0.76
CD44-mediated monocyte transmigration across Cryptococcus neoformans-infected brain microvascular endothelial cells is enhanced by HIV-1 gp41-I90 ectodomain. J Biomed Sci (2016) 0.76
Induction of brain microvascular endothelial cell urokinase expression by Cryptococcus neoformans facilitates blood-brain barrier invasion. PLoS One (2012) 0.76
Antifungal activity of topical microemulsion containing a thiophene derivative. Braz J Microbiol (2014) 0.75
Development of an aerosol model of Cryptococcus reveals humidity as an important factor affecting the viability of Cryptococcus during aerosolization. PLoS One (2013) 0.75
Heteroresistance to Itraconazole Alters the Morphology and Increases the Virulence of Cryptococcus gattii. Antimicrob Agents Chemother (2015) 0.75
Cysteinyl leukotrienes as novel host factors facilitating Cryptococcus neoformans penetration into the brain. Cell Microbiol (2016) 0.75
Cryptococcosis in the era of AIDS--100 years after the discovery of Cryptococcus neoformans. Clin Microbiol Rev (1995) 8.81
Prognostic factors in cryptococcal meningitis. A study in 111 cases. Ann Intern Med (1974) 6.75
Complementation of a capsule-deficient mutation of Cryptococcus neoformans restores its virulence. Mol Cell Biol (1994) 4.22
Virulence of Cryptococcus neoformans. Regulation of capsule synthesis by carbon dioxide. J Clin Invest (1985) 3.98
Frequent ectopic recombination of virulence factor genes in telomeric chromosome clusters of P. falciparum. Nature (2000) 3.90
Identification of patients with acute AIDS-associated cryptococcal meningitis who can be effectively treated with fluconazole: the role of antifungal susceptibility testing. Clin Infect Dis (1996) 3.52
The changing epidemiology of cryptococcosis: an update from population-based active surveillance in 2 large metropolitan areas, 1992-2000. Clin Infect Dis (2003) 3.04
Epidemiological evidence for dormant Cryptococcus neoformans infection. J Clin Microbiol (1999) 2.78
Replication of Cryptococcus neoformans in macrophages is accompanied by phagosomal permeabilization and accumulation of vesicles containing polysaccharide in the cytoplasm. Proc Natl Acad Sci U S A (2002) 2.68
The second capsule gene of cryptococcus neoformans, CAP64, is essential for virulence. Infect Immun (1996) 2.67
Development of vaccines against meningococcal disease. Lancet (2002) 2.67
Production, characterization, and antibody specificity of a mouse monoclonal antibody reactive with Cryptococcus neoformans capsular polysaccharide. Infect Immun (1987) 2.61
Serologic evidence for Cryptococcus neoformans infection in early childhood. Pediatrics (2001) 2.40
Modification of Helicobacter pylori outer membrane protein expression during experimental infection of rhesus macaques. Proc Natl Acad Sci U S A (2004) 2.35
Individual and environmental factors associated with infection due to Cryptococcus neoformans serotype D. French Cryptococcosis Study Group. Clin Infect Dis (1996) 2.33
Pathogenesis of cerebral Cryptococcus neoformans infection after fungemia. J Infect Dis (2002) 2.20
What makes Cryptococcus neoformans a pathogen? Emerg Infect Dis (1998) 2.18
Epidemiology of HIV-associated cryptococcosis in France (1985-2001): comparison of the pre- and post-HAART eras. AIDS (2004) 2.11
Isolation of the third capsule-associated gene, CAP60, required for virulence in Cryptococcus neoformans. Infect Immun (1998) 2.10
Molecular characterization of the humoral responses to Cryptococcus neoformans infection and glucuronoxylomannan-tetanus toxoid conjugate immunization. J Exp Med (1993) 2.09
Dynamic changes in the morphology of Cryptococcus neoformans during murine pulmonary infection. Microbiology (2001) 2.08
Cryptococcal yeast cells invade the central nervous system via transcellular penetration of the blood-brain barrier. Infect Immun (2004) 1.99
Induction of capsule growth in Cryptococcus neoformans by mammalian serum and CO(2). Infect Immun (2003) 1.89
A superfamily of variant genes encoded in the subtelomeric region of Plasmodium vivax. Nature (2001) 1.89
Urease expression by Cryptococcus neoformans promotes microvascular sequestration, thereby enhancing central nervous system invasion. Am J Pathol (2004) 1.87
Functional cloning and characterization of a UDP- glucuronic acid decarboxylase: the pathogenic fungus Cryptococcus neoformans elucidates UDP-xylose synthesis. Proc Natl Acad Sci U S A (2001) 1.80
Serotyping of Cryptococcus neoformans by using a monoclonal antibody specific for capsular polysaccharide. J Clin Microbiol (1993) 1.80
Cas1p is a membrane protein necessary for the O-acetylation of the Cryptococcus neoformans capsular polysaccharide. Mol Microbiol (2001) 1.74
Pathology of cryptococcal meningoencephalitis: analysis of 27 patients with pathogenetic implications. Hum Pathol (1996) 1.71
Identification of App1 as a regulator of phagocytosis and virulence of Cryptococcus neoformans. J Clin Invest (2003) 1.66
Role of extracellular phospholipases and mononuclear phagocytes in dissemination of cryptococcosis in a murine model. Infect Immun (2004) 1.66
Molecular architecture of the Cryptococcus neoformans capsule. Mol Microbiol (2004) 1.66
Cryptococcus neoformans CAP59 (or Cap59p) is involved in the extracellular trafficking of capsular glucuronoxylomannan. Eukaryot Cell (2004) 1.64
Organ-dependent variation of capsule thickness in Cryptococcus neoformans during experimental murine infection. Infect Immun (1998) 1.63
Phenotypic switching in Cryptococcus neoformans results in changes in cellular morphology and glucuronoxylomannan structure. Infect Immun (1999) 1.60
Cryptococcus neoformans induces alterations in the cytoskeleton of human brain microvascular endothelial cells. J Med Microbiol (2003) 1.59
Cryptococcus neoformans gene expression during experimental cryptococcal meningitis. Eukaryot Cell (2003) 1.49
Isolation and characterization of capsule structure mutant strains of Cryptococcus neoformans. Mol Microbiol (2002) 1.45
Pathogenesis and pathophysiology of bacterial meningitis. Clin Microbiol Rev (1993) 1.45
Cryptococcus neoformans capsule biosynthesis and regulation. FEMS Yeast Res (2004) 1.39
Molecular typing of Cryptococcus neoformans serotype D clinical isolates. J Clin Microbiol (1994) 1.39
Phenotypic switching of Cryptococcus neoformans occurs in vivo and influences the outcome of infection. J Clin Invest (2001) 1.38
CNLAC1 is required for extrapulmonary dissemination of Cryptococcus neoformans but not pulmonary persistence. Infect Immun (2004) 1.36
var genes, PfEMP1 and the human host. Mol Biochem Parasitol (2004) 1.34
Cryptococcus neoformans capsule structure evolution in vitro and during murine infection. Infect Immun (2004) 1.31
Spatial and temporal sequence of capsule construction in Cryptococcus neoformans. Mol Microbiol (2001) 1.29
Antigenic and biological characteristics of mutant strains of Cryptococcus neoformans lacking capsular O acetylation or xylosyl side chains. Infect Immun (2003) 1.27
Isolation of Cryptococcus neoformans var. gattii from an Asian patient in France: evidence for dormant infection in healthy subjects. J Med Vet Mycol (1992) 1.23
Production of agglutinating monoclonal antibody against antigen 8 specific for Cryptococcus neoformans serotype D. Clin Diagn Lab Immunol (1996) 1.14
Cytokine profiles of AIDS patients are similar to those of mice with disseminated Cryptococcus neoformans infection. Infect Immun (1999) 1.08
Fungemia during murine cryptococcosis sheds some light on pathophysiology. Med Mycol (1999) 1.08
Translocation of surface antigen genes to a unique telomeric expression site in Pneumocystis carinii. Mol Microbiol (1996) 1.04
Quantitative and qualitative differences in the serum antibody profiles of human immunodeficiency virus-infected persons with and without Cryptococcus neoformans meningitis. J Infect Dis (1999) 1.03
Phenotypic switching of Cryptococcus neoformans can influence the outcome of the human immune response. Cell Microbiol (2003) 0.98
Immune mediators in cerebrospinal fluid during cryptococcosis are influenced by meningeal involvement and human immunodeficiency virus serostatus. J Infect Dis (2000) 0.95
Microbial virulence results from the interaction between host and microorganism. Trends Microbiol (2003) 0.92
Horseradish peroxidase retention and washout in blood-brain barrier lesions. J Neurosci Methods (1992) 0.87
Quantitative analysis of phagocytosis of Cryptococcus neoformans by adherent phagocytic cells by fluorescence multi-well plate reader. J Microbiol Methods (2000) 0.85
Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med (2002) 17.04
Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america. Clin Infect Dis (2010) 11.65
Epidemiology and clinical manifestations of mucormycosis. Clin Infect Dis (2012) 5.66
Incidence and risk factors of immune reconstitution inflammatory syndrome complicating HIV-associated cryptococcosis in France. AIDS (2005) 5.51
Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis (2007) 5.15
Immunoproliferative small intestinal disease associated with Campylobacter jejuni. N Engl J Med (2004) 4.47
Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign. Clin Infect Dis (2006) 4.42
Mutations in STAT3 and IL12RB1 impair the development of human IL-17-producing T cells. J Exp Med (2008) 3.85
Gain-of-function human STAT1 mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasis. J Exp Med (2011) 3.63
Tracing hematopoietic precursor migration to successive hematopoietic organs during zebrafish development. Immunity (2006) 3.62
A mouse model for Chikungunya: young age and inefficient type-I interferon signaling are risk factors for severe disease. PLoS Pathog (2008) 3.40
Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet (2007) 3.11
Early removal of central venous catheter in patients with candidemia does not improve outcome: analysis of 842 patients from 2 randomized clinical trials. Clin Infect Dis (2010) 3.07
Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: a multicenter, prospective, observational study in France (2005-2006). Crit Care Med (2009) 3.07
Pediatric mastocytosis is a clonal disease associated with D816V and other activating c-KIT mutations. J Invest Dermatol (2009) 2.94
Determinants of disease presentation and outcome during cryptococcosis: the CryptoA/D study. PLoS Med (2007) 2.85
Origins and unconventional behavior of neutrophils in developing zebrafish. Blood (2007) 2.76
Systemic antifungal therapy in critically ill patients without invasive fungal infection*. Crit Care Med (2012) 2.55
Mutations in the fks1 gene in Candida albicans, C. tropicalis, and C. krusei correlate with elevated caspofungin MICs uncovered in AM3 medium using the method of the European Committee on Antibiotic Susceptibility Testing. Antimicrob Agents Chemother (2008) 2.54
Phylogenetic and genomic diversity of human bacteremic Escherichia coli strains. BMC Genomics (2008) 2.51
Increasing incidence of zygomycosis (mucormycosis), France, 1997-2006. Emerg Infect Dis (2009) 2.33
Prevalence, determinants of positivity, and clinical utility of cryptococcal antigenemia in Cambodian HIV-infected patients. J Acquir Immune Defic Syndr (2007) 2.32
Cryptococcal cell morphology affects host cell interactions and pathogenicity. PLoS Pathog (2010) 2.28
Pathogenesis of cerebral Cryptococcus neoformans infection after fungemia. J Infect Dis (2002) 2.20
Long-term outcome of AIDS-associated cryptococcosis in the era of combination antiretroviral therapy. AIDS (2006) 2.19
Muscle satellite cells and endothelial cells: close neighbors and privileged partners. Mol Biol Cell (2007) 2.16
Evidence of a role for monocytes in dissemination and brain invasion by Cryptococcus neoformans. Infect Immun (2008) 2.15
Epidemiology of HIV-associated cryptococcosis in France (1985-2001): comparison of the pre- and post-HAART eras. AIDS (2004) 2.11
Infection-associated lymphomas derived from marginal zone B cells: a model of antigen-driven lymphoproliferation. Blood (2006) 2.06
Recent exposure to caspofungin or fluconazole influences the epidemiology of candidemia: a prospective multicenter study involving 2,441 patients. Antimicrob Agents Chemother (2010) 2.02
Molecular identification of zygomycetes from culture and experimentally infected tissues. J Clin Microbiol (2006) 1.96
Diagnosis and treatment of mucormycosis in patients with hematological malignancies: guidelines from the 3rd European Conference on Infections in Leukemia (ECIL 3). Haematologica (2012) 1.80
Cryptococcus neoformans in organ transplant recipients: impact of calcineurin-inhibitor agents on mortality. J Infect Dis (2007) 1.78
Germline CYBB mutations that selectively affect macrophages in kindreds with X-linked predisposition to tuberculous mycobacterial disease. Nat Immunol (2011) 1.76
Treatment of adult systemic mastocytosis with interferon-alpha: results of a multicentre phase II trial on 20 patients. Br J Haematol (2002) 1.76
Primary cutaneous cryptococcosis: a distinct clinical entity. Clin Infect Dis (2003) 1.74
Idiopathic CD4+ T-cell lymphocytopenia is associated with impaired membrane expression of the chemokine receptor CXCR4. Blood (2009) 1.74
Literature review and case histories of Histoplasma capsulatum var. duboisii infections in HIV-infected patients. Emerg Infect Dis (2007) 1.63
Zygomycosis in solid organ transplant recipients: a prospective, matched case-control study to assess risks for disease and outcome. J Infect Dis (2009) 1.62
A role for the myogenic determination gene Myf5 in adult regenerative myogenesis. Dev Biol (2007) 1.61
Lipid formulations of amphotericin B significantly improve outcome in solid organ transplant recipients with central nervous system cryptococcosis. Clin Infect Dis (2009) 1.60
Debaryomyces hansenii (Candida famata), a rare human fungal pathogen often misidentified as Pichia guilliermondii (Candida guilliermondii). J Clin Microbiol (2008) 1.57
β-Glucan antigenemia assay for the diagnosis of invasive fungal infections in patients with hematological malignancies: a systematic review and meta-analysis of cohort studies from the Third European Conference on Infections in Leukemia (ECIL-3). Clin Infect Dis (2011) 1.56
Unique hybrids between the fungal pathogens Cryptococcus neoformans and Cryptococcus gattii. FEMS Yeast Res (2006) 1.54
Bacteremia in patients receiving TNF-alpha antagonists--a prospective multicenter study. J Infect (2013) 1.52
The changing pattern of HIV neuropathology in the HAART era. J Neuropathol Exp Neurol (2003) 1.51
Cryptococcus neoformans Galactoxylomannan contains an epitope(s) that is cross-reactive with Aspergillus Galactomannan. J Clin Microbiol (2005) 1.50
Candida spp. with acquired echinocandin resistance, France, 2004-2010. Emerg Infect Dis (2012) 1.47
Human listeriosis caused by Listeria ivanovii. Emerg Infect Dis (2010) 1.46
Worrisome trends in incidence and mortality of candidemia in intensive care units (Paris area, 2002-2010). Intensive Care Med (2014) 1.45
Three-tesla functional MR language mapping: comparison with direct cortical stimulation in gliomas. Neurology (2015) 1.45
Isolation and characterization of capsule structure mutant strains of Cryptococcus neoformans. Mol Microbiol (2002) 1.45
Intrathecal ropivacaine in rabbits: pharmacodynamic and neurotoxicologic study. Anesthesiology (2002) 1.45
Mucormycosis in organ and stem cell transplant recipients. Clin Infect Dis (2012) 1.45
Neutralization of IFNgamma defeats haemophagocytosis in LCMV-infected perforin- and Rab27a-deficient mice. EMBO Mol Med (2009) 1.44
Cryptococcosis in solid organ transplant recipients: current state of the science. Clin Infect Dis (2008) 1.44
Chikungunya virus infection of corneal grafts. J Infect Dis (2012) 1.44
Neuropathological Correlates of Hyperglycemia During Prolonged Polymicrobial Sepsis in Mice. Shock (2015) 1.43
Major role for amphotericin B-flucytosine combination in severe cryptococcosis. PLoS One (2008) 1.43
Healthcare-associated mucormycosis. Clin Infect Dis (2012) 1.42
Combination therapy for mucormycosis: why, what, and how? Clin Infect Dis (2012) 1.41
Molecular and phenotypic evaluation of Lichtheimia corymbifera (formerly Absidia corymbifera) complex isolates associated with human mucormycosis: rehabilitation of L. ramosa. J Clin Microbiol (2009) 1.36
Simultaneous quantification of voriconazole and posaconazole in human plasma by high-performance liquid chromatography with ultra-violet detection. J Chromatogr B Analyt Technol Biomed Life Sci (2007) 1.34
Human macrophages rescue myoblasts and myotubes from apoptosis through a set of adhesion molecular systems. J Cell Sci (2006) 1.34
Therapeutic drug monitoring of posaconazole: a monocentric study with 54 adults. Antimicrob Agents Chemother (2009) 1.34
Autosomal dominant STAT3 deficiency and hyper-IgE syndrome: molecular, cellular, and clinical features from a French national survey. Medicine (Baltimore) (2012) 1.31
AIDS patient death caused by novel Cryptococcus neoformans x C. gattii hybrid. Emerg Infect Dis (2008) 1.31
Cryptococcus neoformans capsule structure evolution in vitro and during murine infection. Infect Immun (2004) 1.31
Detection of caspofungin resistance in Candida spp. by Etest. J Clin Microbiol (2008) 1.29
Pneumocystis jirovecii Pneumonia. Infect Dis Clin North Am (2010) 1.29
Molecular identification of black-grain mycetoma agents. J Clin Microbiol (2006) 1.28
Complete glycosylphosphatidylinositol anchors are required in Candida albicans for full morphogenesis, virulence and resistance to macrophages. Mol Microbiol (2002) 1.28
Antigenic and biological characteristics of mutant strains of Cryptococcus neoformans lacking capsular O acetylation or xylosyl side chains. Infect Immun (2003) 1.27
Population-based analysis of invasive fungal infections, France, 2001-2010. Emerg Infect Dis (2014) 1.25
Emergence of disseminated infections due to Geosmithia argillacea in patients with chronic granulomatous disease receiving long-term azole antifungal prophylaxis. J Clin Microbiol (2011) 1.24
Skeletal muscle stem cells adopt a dormant cell state post mortem and retain regenerative capacity. Nat Commun (2012) 1.24
Effect of tyrosine kinase inhibitor STI571 on the kinase activity of wild-type and various mutated c-kit receptors found in mast cell neoplasms. Oncogene (2003) 1.23
Early serum galactomannan trend as a predictor of outcome of invasive aspergillosis. J Clin Microbiol (2012) 1.23
[Chikungunya virus: a reemerging alphavirus]. Med Sci (Paris) (2006) 1.22
Immune reconstitution inflammatory syndrome in HIV-infected patients with disseminated histoplasmosis. AIDS (2006) 1.22
Mixed infections and In Vivo evolution in the human fungal pathogen Cryptococcus neoformans. MBio (2010) 1.21
In vitro evaluation of double and triple combinations of antifungal drugs against Aspergillus fumigatus and Aspergillus terreus. Antimicrob Agents Chemother (2004) 1.21
Deletions of endocytic components VPS28 and VPS32 affect growth at alkaline pH and virulence through both RIM101-dependent and RIM101-independent pathways in Candida albicans. Infect Immun (2005) 1.19
Addressing the challenge of extended-spectrum beta-lactamases. Curr Opin Investig Drugs (2009) 1.17